Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 19, 2026, 3:59 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 267 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Chronic Disease Prevention Clear all
Terminated Phase 3 Interventional

Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Peripheral Stem Cell Transplantation

NCT00003056
View directory record Official record
Conditions
Leukemia, Lymphoma, Graft Versus Host Disease
Interventions
cyclosporine, cyclosporine and methotrexate
Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years to 55 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2003
U.S. locations
12
States / cities
Los Angeles, California • Jacksonville, Florida • Atlanta, Georgia + 9 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 19, 2026, 3:59 AM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant

NCT03779854
View directory record Official record
Conditions
Acute Biphenotypic Leukemia, Acute Leukemia, Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Undifferentiated Leukemia, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Blastic Plasmacytoid Dendritic Cell Neoplasm, Blasts Under 25 Percent of Bone Marrow Nucleated Cells, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome With Excess Blasts-1, Myelodysplastic Syndrome/Acute Myeloid Leukemia, Burkitt Leukemia, Chronic Monocytic Leukemia, Lymphoblastic Lymphoma, Mast Cell Leukemia, Myeloproliferative Neoplasm
Interventions
Total-Body Irradiation, Thiotepa, Fludarabine, Cyclophosphamide, Busulfan, Allogeneic Bone Marrow Transplantation, Tacrolimus, Methotrexate, Naive T Cell-Depleted Hematopoietic Stem Cell Transplantation, Echocardiography, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
Radiation · Drug · Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
6 Months to 26 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Atlanta, Georgia • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Vitamin D and Fish Oil for Autoimmune Disease, Inflammation and Knee Pain

NCT01351805
View directory record Official record
Conditions
Autoimmune Diseases, Systemic Inflammatory Process, Knee Pain Chronic, Osteoarthritis, Rheumatoid Arthritis
Interventions
Fish Oil, Vitamin D, placebo pill
Drug · Dietary Supplement · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
50 Years and older
Enrollment
25,871 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 2, 2025 · Synced Sep 19, 2026, 3:59 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Intrapartum Vancomycin for Group B Streptococcus (GBS) Prophylaxis

NCT02143154
View directory record Official record
Conditions
GBS Positive, Women in Labor Given Vancomycin for Prophylaxis
Interventions
Not listed
Lead sponsor
Women and Infants Hospital of Rhode Island
Other
Eligibility
18 Years to 48 Years · Female only
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Sep 19, 2026, 3:59 AM EDT
Completed No phase listed Observational

Patient and Provider Assessment of Lipid Management Registry

NCT02341664
View directory record Official record
Conditions
Hyperlipidemia, Hypercholesterolemia, Cardiovascular Disease, Diabetes, Chronic Kidney Disease (CKD), Hypertension, Smoking, Myocardial Infarction (MI), Unstable Angina, Angina, Coronary Artery Disease (CAD), Stroke, Transient Ischemic Attack (TIA), Carotid Stenosis, Peripheral Arterial Disease, Atherosclerosis, Claudication
Interventions
Not listed
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
7,658 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
14
States / cities
Little Rock, Arkansas • San Pedro, California • Ventura, California + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 1, 2020 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

NCT01246206
View directory record Official record
Conditions
Hematological Malignancies
Interventions
Tacrolimus and Thymoglobulin
Drug
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 17, 2018 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Not applicable Interventional Results available

Randomized Controlled Trial of Group Prevention Coaching

NCT01838226
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Problem Solving
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
21 Years and older
Enrollment
401 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
2
States / cities
Buffalo, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 26, 2023 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Dexamethasone to Prevent Oral Chronic Graft-versus-Host Disease

NCT00391170
View directory record Official record
Conditions
Graft vs Host Disease
Interventions
Topical Dexamethasone, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 110 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 9, 2022 · Synced Sep 19, 2026, 3:59 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Galantamine in the Treatment of Post-Traumatic Headache

NCT00219869
View directory record Official record
Conditions
Post-Traumatic Headache, Head Trauma,Closed, Retention Disorders,Cognitive
Interventions
Galantamine
Drug
Lead sponsor
Rapoport, Alan, M.D.
Individual
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Stamford, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 21, 2005 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Results available

Airway Clearance for Prevention of Chronic Obstructive Pulmonary Disease (COPD) Exacerbation

NCT00181207
View directory record Official record
Conditions
COPD, Chronic Bronchitis, Emphysema
Interventions
pneumatic vest, placebo pneumatic vest
Device · Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
45 Years to 85 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced Sep 19, 2026, 3:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Integrating Food Rx With Best Feeding Practices With EFNEP

NCT05881759
View directory record Official record
Conditions
Dietary Habits, Childhood Obesity, Food Selection, Feeding Behavior
Interventions
BEST study - Nutrition education only, BEST study - Nutrition education and feeding practices, BEST study - Nutrition education, feeding practices, and Food Rx
Behavioral
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years
Enrollment
375 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents

NCT04530110
View directory record Official record
Conditions
Migraine
Interventions
Fremanezumab
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D LLC
Industry
Eligibility
6 Years to 17 Years
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
32
States / cities
Aurora, Colorado • Colorado Springs, Colorado • Jacksonville, Florida + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Sep 19, 2026, 3:59 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Team Lifestyle Immersion Hypertension Control Project

NCT07201948
View directory record Official record
Conditions
Hypertension
Interventions
Lifestyle Immersion Intervention that will address Nutrition, Physical Fitness, and BP Self-Monitoring3 Elements:
Behavioral
Lead sponsor
Meharry Medical College
Other
Eligibility
30 Years to 80 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 4 Interventional Results available

Prevention of Persistent Opioid Use in Mothers

NCT03472521
View directory record Official record
Conditions
Opioid Use, Postpartum Disorder, Chronic Pain Syndrome
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 4, 2022 · Synced Sep 19, 2026, 3:59 AM EDT
Terminated Phase 1 Interventional

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

NCT02728700
View directory record Official record
Conditions
Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Hodgkin Lymphoma, Childhood Myelodysplastic Syndrome, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelofibrosis, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Sirolimus
Procedure · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 11, 2018 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 1 Interventional

Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants

NCT00001830
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Graft vs Host Disease, Hodgkin's Disease, Multiple Myeloma, Non Hodgkin's Lymphoma
Interventions
Th2 cells in allo HSCTT, Th2 Cells
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 75 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2015
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 4, 2018 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 3 Interventional Results available

Comparing Safety and Immunogenicity of HEPLISAV-B® to Engerix-B® in Chronic Kidney Disease (CKD) Patients

NCT00985426
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
HEPLISAV-B, Engerix-B, Placebo
Biological · Other
Lead sponsor
Dynavax Technologies Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 18, 2021 · Synced Sep 19, 2026, 3:59 AM EDT
Terminated Phase 2 Interventional Results available

Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation

NCT03246906
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Aggressive Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine, Mycophenolate Mofetil, Sirolimus
Procedure · Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

NCT03832998
View directory record Official record
Conditions
Migraine
Interventions
Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
6 Years to 17 Years
Enrollment
284 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
38
States / cities
San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2026 · Synced Sep 19, 2026, 3:59 AM EDT
Recruiting Not applicable Interventional

Mobilizing Community Hypertension Access Pilot

NCT07547345
View directory record Official record
Conditions
Hypertension
Interventions
Community-Based Multidisciplinary Hypertension Management Program
Behavioral
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis

NCT02593123
View directory record Official record
Conditions
Hodgkin's Lymphoma, Lymphoid Leukemia, Lymphoma, Leukemia, Myeloma, Acute Lymphocytic Leukemia, Non Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Multiple Myeloma, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Recurrent Acute Myeloid Leukemia, Adult, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Interventions
mycophenolate mofetil, Sargramostim, Filgrastim
Drug · Biological
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 74 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 22, 2023 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Improving Minority Health Through Biofeedback and Stress Reduction

NCT07172152
View directory record Official record
Conditions
Cardiovascular Disease Risk Reduction, Chronic Stress, Anxiety, Emotional Regulation, Hypertension Prevention, Health Disparities
Interventions
HRV Biofeedback Training
Behavioral
Lead sponsor
Amelia Saul, PhD, CTRS, BCB
Other
Eligibility
18 Years to 35 Years
Enrollment
66 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 19, 2026, 3:59 AM EDT
Suspended Phase 1 Interventional

Biomarker-Guided Ruxolitinib for the Prevention of Chronic Graft Versus Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT07025538
View directory record Official record
Conditions
Hematopoietic and Lymphatic System Neoplasm
Interventions
Best Practice, Biomarker Analysis, Biospecimen Collection, Questionnaire Administration, Ruxolitinib
Other · Procedure · Drug
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Duarte, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 19, 2026, 3:59 AM EDT
Completed Phase 2 Interventional Results available

Valproic Acid for the Prevention of Post-Amputation Pain

NCT01928849
View directory record Official record
Conditions
Pain, Phantom, Pain, Neuropathic
Interventions
Valproic Acid, Cherry Syrup
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
2
States / cities
Bethesda, Maryland • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2018 · Synced Sep 19, 2026, 3:59 AM EDT